The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion. The Financial Times first revealed the ...

Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.